Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, March 28, 2024
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Leland Gershell Initiated (XERS) at Buy and Held Target at $5 on, Mar 28th, 2024
Leland Gershell of Oppenheimer, Initiated "Xeris Biopharma Holdings, Inc." (XERS) at Buy and Held Target at $5 on, Mar 28th, 2024.
Leland has made no other calls on XERS in the last 4 months.
There is 1 other peer that has a rating on XERS. Out of the 1 peers that are also analyzing XERS, 0 agree with Leland's Rating of Hold.
This is the rating of the analyst that currently disagrees with Leland
- Oren Livnat of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $6 on, Thursday, March 7th, 2024
